Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kamada Ltd. stock logo
KMDA
Kamada
$7.22
-2.3%
$7.38
$5.08
$9.15
$415.19M0.9348,694 shs41,907 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$1.45
-0.7%
$1.50
$0.82
$3.10
$115.43M-0.23864,151 shs357,101 shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$5.87
-1.3%
$4.80
$2.21
$6.64
$517.63M0.181.01 million shs909,369 shs
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
$21.76
-1.7%
$18.14
$11.56
$29.79
$568.41M2188,810 shs226,846 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kamada Ltd. stock logo
KMDA
Kamada
-2.30%-6.48%-6.72%+8.41%+27.79%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
-0.68%-3.97%-3.33%-51.67%+34.26%
Rezolute, Inc. stock logo
RZLT
Rezolute
-1.34%-6.83%+20.78%+46.75%+27.75%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-1.67%+10.07%+34.40%+33.50%+28.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Kamada Ltd. stock logo
KMDA
Kamada
4.4702 of 5 stars
3.35.00.00.02.41.74.4
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
2.2289 of 5 stars
3.53.00.00.00.00.01.9
Rezolute, Inc. stock logo
RZLT
Rezolute
2.3609 of 5 stars
3.61.00.00.01.84.20.0
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
1.574 of 5 stars
3.50.00.00.01.92.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kamada Ltd. stock logo
KMDA
Kamada
2.67
Moderate Buy$13.0080.06% Upside
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$15.00934.48% Upside
Rezolute, Inc. stock logo
RZLT
Rezolute
3.14
Buy$11.83101.59% Upside
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
3.00
Buy$49.33126.72% Upside

Current Analyst Ratings Breakdown

Latest PLX, TRML, RZLT, and KMDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Kamada Ltd. stock logo
KMDA
Kamada
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/14/2025
Rezolute, Inc. stock logo
RZLT
Rezolute
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$12.00
5/8/2025
Kamada Ltd. stock logo
KMDA
Kamada
Sidoti
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/5/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
5/5/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kamada Ltd. stock logo
KMDA
Kamada
$167.24M2.48$0.48 per share15.03$4.51 per share1.60
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$59.76M1.93$0.08 per share17.80$0.47 per share3.09
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$2.19 per shareN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/A$11.71 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kamada Ltd. stock logo
KMDA
Kamada
$14.46M$0.2924.9022.560.909.60%6.31%4.43%8/13/2025 (Estimated)
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.04N/A4.68N/A-21.03%-30.89%-11.74%N/A
Rezolute, Inc. stock logo
RZLT
Rezolute
-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$73.21M-$3.21N/AN/AN/AN/A-26.75%-26.11%8/6/2025 (Estimated)

Latest PLX, TRML, RZLT, and KMDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$0.95N/AN/AN/AN/AN/A
8/13/2025Q2 2025
Kamada Ltd. stock logo
KMDA
Kamada
$0.09N/AN/AN/A$158.59 millionN/A
5/14/2025Q1 2025
Kamada Ltd. stock logo
KMDA
Kamada
$0.07$0.07N/A$0.07$154.06 million$44.02 million
5/13/2025Q3 2025
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.22-$0.27-$0.05-$0.27N/AN/A
5/9/2025Q1
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A-$0.05N/AN/AN/AN/A
5/2/2025Q1 2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$0.91-$0.89+$0.02-$0.89N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Kamada Ltd. stock logo
KMDA
Kamada
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kamada Ltd. stock logo
KMDA
Kamada
N/A
3.30
1.93
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
8.43
8.43
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/A
33.87
33.87

Institutional Ownership

CompanyInstitutional Ownership
Kamada Ltd. stock logo
KMDA
Kamada
20.38%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
91.89%

Insider Ownership

CompanyInsider Ownership
Kamada Ltd. stock logo
KMDA
Kamada
36.10%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.50%
Rezolute, Inc. stock logo
RZLT
Rezolute
18.39%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
13.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Kamada Ltd. stock logo
KMDA
Kamada
36057.51 million36.75 millionOptionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20079.61 million69.00 millionOptionable
Rezolute, Inc. stock logo
RZLT
Rezolute
4087.00 million71.00 millionOptionable
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
4425.69 million22.35 millionOptionable

Recent News About These Companies

BMO Capital Remains a Buy on Tourmaline Bio (TRML)
Tourmaline Bio Inc News (TRML) - Investing.com
TRML - Tourmaline Bio Inc Dividends - Morningstar
TRML - Tourmaline Bio Inc Executives - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Kamada stock logo

Kamada NASDAQ:KMDA

$7.22 -0.17 (-2.30%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$7.08 -0.14 (-1.99%)
As of 08/1/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$1.45 -0.01 (-0.68%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.46 +0.02 (+1.03%)
As of 08/1/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Rezolute stock logo

Rezolute NASDAQ:RZLT

$5.87 -0.08 (-1.34%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$5.80 -0.07 (-1.19%)
As of 08/1/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Tourmaline Bio stock logo

Tourmaline Bio NASDAQ:TRML

$21.76 -0.37 (-1.67%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$21.80 +0.04 (+0.21%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.